Pfizer Inc. vs TotalEnergies SE: Strategic Comparison
Key Differences at a Glance
| Field | Pfizer Inc. | TotalEnergies SE |
|---|---|---|
| Revenue | $62.6B | $182.3B |
| Founded | 1849 | 1924 |
| Employees | 75,000 | 101,513 |
| Market Cap | $148.0B | $165.0B |
| Headquarters | United States | France |
Quick Stats Comparison
| Metric | Pfizer Inc. | TotalEnergies SE |
|---|---|---|
| Revenue | $62.6B | $182.3B |
| Founded | 1849 | 1924 |
| Headquarters | New York, New York | Paris, France |
| Market Cap | $148.0B | $165.0B |
| Employees | 75,000 | 101,513 |
Pfizer Inc. Revenue vs TotalEnergies SE Revenue — Year by Year
| Year | Pfizer Inc. | TotalEnergies SE | Leader |
|---|---|---|---|
| 2025 | $62.6B | $182.3B | TotalEnergies SE |
| 2024 | $63.6B | $195.6B | TotalEnergies SE |
| 2023 | $59.6B | $218.9B | TotalEnergies SE |
| 2022 | $101.2B | N/A | Pfizer Inc. |
| 2021 | $81.3B | N/A | Pfizer Inc. |
Business Model Breakdown
Overview: Pfizer Inc. vs TotalEnergies SE
This in-depth comparison examines Pfizer Inc. and TotalEnergies SE across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Pfizer Inc. on its own, evaluating TotalEnergies SE, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Pfizer Inc. and TotalEnergies SE is widest.
On the headline numbers, Pfizer Inc. reports annual revenue of $62.6B against $182.3B for TotalEnergies SE, while their respective market capitalizations stand at $148.0B and $165.0B. Pfizer Inc. is headquartered in United States and TotalEnergies SE operates from France, and those different home markets shape how each company competes.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
TotalEnergies SE: TotalEnergies reported $182.344 billion in 2025 revenues from sales and $13.127 billion in net income attributable to TotalEnergies. The company remains a multi-energy major: oil and gas production, LNG, refining, marketing, electricity, and renewables all sit inside one capital-allocation system led by CEO Patrick Pouyanne.
Business Models: How Pfizer Inc. and TotalEnergies SE Make Money
Pfizer Inc. and TotalEnergies SE pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Pfizer Inc. and TotalEnergies SE.
Pfizer Inc. business model: Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.
TotalEnergies SE business model: TotalEnergies makes money from an integrated energy chain: exploration and production, LNG, refining and chemicals, marketing and services, electricity generation, power trading, renewable assets, and customer energy services.
Competitive Advantage: Pfizer Inc. vs TotalEnergies SE
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Pfizer Inc. stack up against those of TotalEnergies SE.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
TotalEnergies SE competitive advantage: TotalEnergies has an integrated LNG platform, upstream assets across multiple basins, downstream and marketing positions, and a growing power portfolio. Its advantage is breadth across molecules, refined products, and electrons.
Growth Strategy: Where Pfizer Inc. and TotalEnergies SE Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Pfizer Inc. and TotalEnergies SE each plan to expand from here.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
TotalEnergies SE growth strategy: TotalEnergies' strategy centers on low-cost oil and gas production, LNG integration, disciplined downstream operations, renewable power capacity, electricity customers, and cash returns to shareholders.
Financial Picture: Pfizer Inc. vs TotalEnergies SE
A closer look at the financial trajectory of Pfizer Inc. and TotalEnergies SE rounds out the comparison.
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
TotalEnergies SE: TotalEnergies reported $182.344 billion in 2025 revenues from sales, down from $195.610 billion in 2024 as hydrocarbon prices declined. Net income attributable to TotalEnergies was $13.127 billion, while adjusted net income was $15.587 billion and adjusted EBITDA was $40.555 billion.
Company-Specific SWOT Notes
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
TotalEnergies SE
TotalEnergies controls over 4,000 service stations and the majority of the premium lubricants market across 40 African countries, providing a stable, high-margin, recession-proof baseline of free cash flow that is completely decoupled from European refining ma
The company is the second-largest global player in liquefied natural gas, controlling a portfolio of long-term upstream production contracts in Qatar, Australia, and the US, combined with a massive midstream shipping fleet and downstream terminals.
The company faces intense regulatory hostility in its home markets of France and Belgium, where the aggressive expansion of the EU Emissions Trading System and the implementation of windfall profit taxes directly confiscate the cash flows generated by its inte
While the African downstream network is highly profitable, it exposes the company to significant geopolitical, security, and foreign exchange risks, as operations in the Sahel region and sub-Saharan Africa are increasingly threatened by political instability a
TotalEnergies is deploying over $5 billion annually to develop utility-scale solar and offshore wind projects, with a target to reach 100 gigawatts of renewable capacity by 2030.
ExxonMobil and Chevron have executed a strategic retreat from the European retail and renewable power markets to focus exclusively on high-return, low-cost unconventional oil production in the Permian Basin and the deepwater Gulf of Mexico.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | TotalEnergies SE | TotalEnergies SE reports the larger revenue base ($182.3B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1849 vs 1924. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Pfizer Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | TotalEnergies SE | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | TotalEnergies SE | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
TotalEnergies SE reports the larger revenue base ($182.3B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1849 vs 1924. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Pfizer Inc. or TotalEnergies SE?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Pfizer Inc. vs TotalEnergies SE
Is Pfizer Inc. better than TotalEnergies SE?
Verdict: Between Pfizer Inc. and TotalEnergies SE, TotalEnergies SE is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, TotalEnergies SE comes out ahead in this Pfizer Inc. vs TotalEnergies SE comparison.
Who earns more — Pfizer Inc. or TotalEnergies SE?
TotalEnergies SE earns more with $182.3B in annual revenue versus Pfizer Inc.'s $62.6B. TotalEnergies SE leads on total revenue based on latest verified figures.
Which company has higher revenue — Pfizer Inc. or TotalEnergies SE?
Pfizer Inc. reported $62.6B, while TotalEnergies SE reported $182.3B. The revenue leader is TotalEnergies SE based on latest verified figures.
Pfizer Inc. revenue vs TotalEnergies SE revenue — which is higher?
Pfizer Inc. revenue: $62.6B. TotalEnergies SE revenue: $62.6B. TotalEnergies SE has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com
- TotalEnergies SE Corporate Website
- TotalEnergies SE Annual Report 2025 - Revenue and Financial Data
- totalenergies.com
- sec.gov
- totalenergies.com